CN-201 NCT07519772 Clinical Landscape 2026

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 16 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Phase 1/2

Clinical phase

Recruiting

Recruitment status

280

Planned enrollment

2030-07-01

Primary-completion proxy

Executive view

NCT07519772 evaluates CN-201 in Follicular Lymphoma. The disclosed sponsor is Merck Sharp & Dohme LLC, the design is Interventional, and the geographic footprint is Argentina, United States, United Kingdom, Spain, Canada, South Korea, China, Turkey, Poland, Italy, Israel, Chile, Australia, Germany. The first listed primary endpoint is Number of Participants Who Experience an Adverse Event (AE), assessed over Up to approximately 49 months.

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07519772 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Follicular Lymphoma landscape. Drug & Asset MCP drug_fetch was queried for CN-201, while Company & Deal Intelligence MCP organization_fetch was queried for Merck Sharp & Dohme LLC.

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
NCT07519772	CN-201	Phase 1/2 / Recruiting	Merck Sharp & Dohme LLC	Argentina, United States, United Kingdom, Spain, Canada, South Korea, China, Turkey, Poland, Italy, Israel, Chile, Australia, Germany	Number of Participants Who Experience an Adverse Event (AE) Up to approximately 49 months	2030-07-01
NCT07729397	CD30.CAR-EBVST cell therapy(Baylor College of Medicine)	Phase 1 / Not yet recruiting	The Methodist Hospital Research Institute	United States	Incidence of Dose-Limiting Toxicities (DLTs) From initiation of lymphodepleting chemotherapy through 28 days follo…	2030-03-31
NCT07691606	ARC-02	Phase 1 / Recruiting	Taiho Oncology, Inc.	United States, Poland, Italy, France, Australia, Spain	Dose Escalation: Number of Participants with Dose-Limiting Toxicities (DLTs) Up to 5 years	2029-01-01
NCT07649304	Cyclophosphamide	Phase 1 / Not yet recruiting	National Cancer Institute	Geography not reported	Ability to deliver at least 4 full cycles of glofitamab-rituximab, cyclophosphamide, doxorubicin, vincristine, and pred… Up to cycle 4 (Cycles = 21 days)	2028-04-30
NCT07638982	Axatilimab-csfr	Phase 1 / Not yet recruiting	Northside Hospital, Inc.	United States	Determine the recommended Phase 2 dose (RP2D) of axatilimab 1 year	2028-12-31

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT07519772 is a Phase 1/2, recruiting study with 280 planned participants. Allocation is Randomized, masking is None (Open Label), and the intervention model is Parallel Assignment.

The primary endpoint is “Number of Participants Who Experience an Adverse Event (AE)” over “Up to approximately 49 months.” The retrieved endpoint description is: An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported..

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 280 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

5 recent result records were selected as contextual evidence for Follicular Lymphoma. These records do not establish direct evidence for NCT07519772 unless the registration number matches.

A Phase II Study Evaluating the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circu…

Phase 2; n=46; End of Treatment Complete Response (EOT CR) Rate = 73.3 Percentage of participants (95% Confidence Interval, 58.06 - 85.40) Source: https://clinicaltrials.gov/ct2/show/results/NCT04980222

A Phase 1b Study Evaluating the Safety, Tolerability and Preliminary Anti-tumor Activity of NT-I7 a Long-acting Human IL-7, Post-Kymriah®, Post-Yescarta®, or Post-Breyanzi® in Sub…

Phase 1; n=17; Any TEAEs = 3 Participants ; Any TEAEs = 2 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT05075603

Ultralow-Dose Interleukin 10–Expressing Chimeric Antigen Receptor T Cells in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 1; n=13; CR = 84.6 % Source: https://pubmed-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/42490071/

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

No exact Drug & Asset MCP profile was returned for the protocol wording “CN-201.” The report therefore avoids inferring modality, target or global development stage from the name alone.

No exact Company & Deal Intelligence profile was returned for Merck Sharp & Dohme LLC. Sponsor identity is retained from the trial protocol without adding unsupported corporate claims.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether CN-201 is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT07519772
Protocol source: https://clinicaltrials.gov/study/NCT07519772
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 16 September 2026.

CN-201 in Follicular Lymphoma is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Number of Participants Who Experience an Adverse Event (AE) and 2030-07-01 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP